Fw: Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors
Sorry for typos/message from phone 🤳🏻 Seppo Vainio, prof. Kvantum Institute, Sci. Dir ________________________________ Lähettäjä: cecilia.ljungberg@lablifenordic.com cecilia.ljungberg@lablifenordic.com Lähetetty: Tuesday, February 10, 2026 9:43:50 AM Vastaanottaja: Seppo Vainio seppo.vainio@oulu.fi Aihe: Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors
If you cannot read this email, click herehttps://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi?action=vsm&sai=229533&s=366&c=2126&m=414&k=25750E30537697B7&tk=DggBAQduc191VmxASV42DERKOR1ccglhaxkqLmYLb1AcdRUYfThyQGVyUF1OUSNRbG0YSRZGW3ZeXj84aih9AUYVWmtVLA%3D%3D to view it online
[https://online.superoffice.com/Cust21057/CS/scripts/customer.fcgi/getAttachm...]
Don´t miss our Tapestri webinar: Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors Tuesday February 10 2026 at 05:00 pm CEThttps://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi?action=ejLink&key=366:819:2126:90398300cac9ffea7c926aade71b3ceda35fb947&sai=229533&
[https://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi/getAttach...] https://watch.getcontrast.io/register/missionbio-single-cell-proteogenomic-analysis-of-clonal-evolution-in-pdx-models-of-aml-treated-with-idh-inhibitors?utm_source=organicsocial
Aromatase inhibitors (AIs) are used sequentially to treat ER+ breast cancer, yet resistance limits benefit.
This session integrates WES from 11 patients across three treatment timepoints (Neoletexe trial) with single-cell DNA sequencing validation to reconstruct subclonal architectures.
We’ll connect rising cancer cell fraction trajectories with reduced response, contrast exemestane- vs. letrozole-resistant clones, and highlight clinically actionable alterations—spanning PI3K/AKT/mTOR, CDK4/6, DNA repair, and immune checkpoint pathways.
Speaker:
Dr Steven Chan Associate Professor - Princess Margaret Cancer Centre; Senior Scientist, & Staff Physician - Department of Medicine at the University of Toronto
Dr. Chan is a senior scientist and staff physician at Princess Margaret Cancer Centre in Toronto. He is also an Associate Professor in the Department of Medicine at the University of Toronto. He received his medical and research training at Stanford University in California where he earned his M.D. and Ph.D. degree in Immunology. He completed his internal medicine residency and adult hematology fellowship at Stanford Hospital and Clinics. He started his independent research program at Princess Margaret Cancer Centre in 2015. His current research focuses on developing novel therapeutic approaches against acute myeloid leukemia and clonal hematopoiesis.
[https://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi/getAttach...] https://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi?action=ejLink&key=366:820:2126:46603f9474700af2a9dfa8a9c4414d83895cfb9e&sai=229533& [https://online.superoffice.com/Cust21057/CS/scripts/customer.fcgi/getAttachm...] [https://online.superoffice.com/Cust21057/CS/scripts/customer.exe/getAttachme...] You are receiving this information because you are subscribed to our newsletter with address seppo.vainio@oulu.fi. You can unsubscribe from our newsletters by clicking this linkhttps://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi?action=updateSubscriptionsFrame&tk=DggBAQduc191VmxASV42DERKOR1ccglhaxkqLmYLb1AcdRUYfThyQGVyUF1OUSNRbG0YSRZGW3ZeXj84aih9AUYVWmtVLA%3D%3D&f=555B63B155. [https://online3.superoffice.com/Cust21057/CS/scripts/customer.fcgi?action=vi...]
-
Seppo Vainio